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Cutaneous manifestations of spondyloarthritis
Spondyloarthritis
Spondyloarthritis comprises a group of inflam-
matory rheumatic diseases that share a common 
genetic predisposition but distinctive clinical 
features that primarily affect the spine, sacroiliac 
joints and ligaments. Extra-articular manifesta-
tions in organs such as the intestines, urinary 
tract, heart, eyes and skin are also frequently 
observed. 
The conditions grouped within the spon-
dyloarthritis family include ankylosing spon-
dylitis, psoriatic arthritis, arthritis/spondylitis 
associated with inflammatory bowel disease, 
reactive arthritis, undifferentiated spondyloar-
thritis, uveitis associated with the B-27 antigen, 
atrio-ventricular block, aortic insufficiency and 
j uvenile chronic arthritis [1].
The onset of the disease occurs between the 
third and fourth decades of life but can also 
occur during childhood and adolescence in a 
form called juvenile spondyloarthritis; how-
ever, the time of onset and clinical characteris-
tics are different from those observed in adults. 
The prevalence of spondyloarthritis is approxi-
mately 0.5–1.9%, and this condition may occur 
in both sexes but is most often diagnosed in men 
because women have fewer symptoms [2].
The Assessment in Ankylosing Spondylitis 
(ASAS) International Society has recently estab-
lished criteria for the classification of spondy-
loarthritis as summarized in Table  1  [3]. This 
classification includes joint, axial and periph-
eral manifestations and considers systemic and 
joint manifestations, demographic characteris-
tics and other clinical parameters such as the 
age of onset and the presence of uveitis, psoriasis 
or ulcerative colitis/Crohn’s disease; a history 
of preceding infection (urethritis/cervicitis or 
diarrhea 1 month before the onset of arthri-
tis/enthesitis/dactylitis); HLA-B27 positivity; 
sacroiliitis demonstrated by x-ray or MRI; and 
a family history of spondyloarthritis among 
first- or second-degree relatives [4].
Notably, extra-articular manifestations are 
observed in 20–60% of cases at some time dur-
ing the disease course and are associated with 
axial or joint inflammation, including anterior 
uveitis in 51%, psoriasis in 20%, inflammatory 
bowel disease in 19% and combined symptoms 
in 10% of patients [5].
Etiology
The etiology of spondyloarthritis is unknown; 
however, the interaction of multiple genes and 
environmental factors are implicated in the 
pathogenesis of these diseases. Notably, over 
90% of patients with ankylosing spondyli-
tis carry the HLA-B27 allele [6]. Psoriasis is 
associated with a group of susceptibility genes 
called PSOR 1–7; the LCE3B/3C gene, which is 
related to epidermal differentiation; the IL-23 
gene; and the gene encoding the transcription 
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factor NF-kB. These last two genes are associ-
ated with spondyloarthritis in addition to auto-
immunity [7]. The HLA-Cw6 allele constitutes 
a risk factor for the development of psoriasis [8]. 
In summary, spondyloarthritis is associated with 
a genetic background accompanied by immuno-
logical  abnormalities, which play a role in its 
pathogenesis [9].
Psoriasis is the gold standard of skin 
involvement
Psoriasis is a disease that results from a com-
plex combination of concerted pathophysi-
ological events, which take place mainly in the 
skin, ligaments and joints. The disease process 
is related to epidermal proliferation, hyperkera-
tosis, skin regeneration, skin metabolism and 
inflammation. The expression of the involved 
genes is choreographed to produce pathologic 
changes in the skin and related tissues; these 
changes result clinically in the expression of a 
certain phenotype, which is the basis for clas-
sification. We focus on psoriasis because, among 
the spondyloarthritis group of diseases, this dis-
ease presents the pathology that affects the skin 
most strongly.
Pathophysiology
T cells, monocytes and activated macrophages 
play a key role in psoriatic inflammation of the 
skin and joints, over-regulation of inflammatory 
cytokines such as TNF, IL-6, IL-12, IL-2 and 
IFN-g induce different cellular interactions.
An initial trigger such as an infection 
(Streptococcus, Klebsiella, virus), trauma 
(Koebner phenomenon), stress or drugs could 
Table 1. Classification criteria for spondyloarthritis by the Assessment of Spondyloarthritis International 
Society. 
Axial spondyloarthritis Peripheral spondyloarthritis
Age at onset <45 years
Back pain, ≥3 months (with/without peripheral 
manifestations)
Peripheral manifestations only
Arthritis or enthesitis or dactylitis
Sacroiliitis on imaging 
plus ≥1 spondyloarthritis 
feature:
Or HLA-B27 plus ≥2 other 
spondyloarthritis features:








Good response to NSAIDs





Preceding infection for 1 month 
before the onset of symptoms
HLA-B27
Uveitis





Inflammatory back pain ever
Family history of spondyloarthritis
CRP: C-reactive protein. 
Data taken from [3].
A B C
Figure 1. Nail and enthesitis. (A) Nail psoriasis; the arrow shows edema and erythema around the 
nail due to enthesitis. (B) Radiograph showing erosive changes at the distal interphalangeal joint of 
the forefinger with psoriasis. The arrow indicates the area of enthesitis. (C) The nail-bed epithelium 
displays moderate acanthosis, the exocytosis of neutrophils and the formation of Munro 
microabscesses in its superficial portion (arrow). There is perivascular infiltration of lymphocytes in 
the corium.
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set off the disease; then, a sum of different tran-
scription factors, receptors and cytokines may 
induce and maintain keratinocyte hyperprolifer-
ation and inflammatory infiltrates along plaques. 
These infiltrates become recurrent and, in addi-
tion to the presence of cytokines such as IL-8, 
enhance neutrophil accumulation in psoriatic 
plaques [10,11].
Psoriasis is a papulo-squamous and des-
quamative disorder characterized clinically 
by sharply demarcated erythematous plaques 
covered with silvery whitish scales. Psoriatic 
lesions are chiefly distributed on the scalp, 
elbows, knees, trunk and gluteus creases. The 
fingernails are frequently involved and show the 
following features in 50–80% of patients: nail 
matrix psoriasis: pitting, leukonychia, nail plate 
crumbling, red spots in the lunula and nail-bed 
psoriasis: onycholysis, oil-spots, hyperkerato-
sis, erythronychia and/or splinter hemorrhage 
(Figure 1) [12,13].
The clinical phenotypes of psoriasis are as 
follows: guttate, plaque, pustular, erythro-
dermic and inverse (Figure 2). Psoriatic arthritis 
is an extracutaneous manifestation observed in 
5–20% of patients with any of the skin features 
of psoriasis, the nails are invariably affected in 
these patients. In most cases, the clinical evolu-
tion exhibits clinical improvement in the sum-
mer and worsens in the winter [14]. Chronic 
plaque and guttate psoriasis exhibit differences 
in terms of the levels of protein expression of 
SCCA2, cytokeratin 14, cytokeratin 17, enolase, 
superoxide dismutase and galectin, suggest-
ing that although guttate and plaque psoriatic 
lesions are manifestations of the same disease, 
these phenotypes represent the differential 
expression of some skin proteins [15–18]. 
other dermatologic manifestations 
of spondyloarthritis diseases
Reactive arthritis and Crohn’s disease are prob-
ably the spondyloarthritic diseases with differ-
ent cutaneous manifestations. These patholo-





Figure 2. Psoriasis: clinical phenotypes. (A) Plaque psoriasis. (B) Guttate. (C) Generalized. (d) Lesions on the scalp. (E) The Auspitz 
sign or bloody-mist sign was observed in early lesions.
A B
Figure 3. other skin manifestations of spondyloarthritis. (A) Erythema 
nodosum. (B) Pyoderma gangrenosum.
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seronegative polyarthritis affecting the lower 
limbs. Spondylitis is seen in most of these 
patients, as are other signs or symptoms related 
to epithelial and endothelial effects such as ocu-
lar inflammation (conjunctivitis with or with-
out uveitis), oral ulceration, erythema nodosum, 
pyoderma gangrenosum and thrombophlebitis 
(Figure 3). These clinical features are not specific 
and can also be observed in individuals with 
Behçet disease [19]. 
Skin involvement in Crohn’s disease is pres-
ent in 0.5–20% of patients as an extension of 
intestinal disease activity. The clinical features 
include perianal and perineal fissures, fistulas 
and abscesses. Ulceration of the scrotum or 
vulva is a serious complication of this disease; 
other skin segments can be involved, with 
itchy psoriasiform plaques distributed on the 
legs and trunk. Orofacial disease occurs at the 
same time as intestinal flare-up symptoms, fre-
quently as inflammation of the gums, mucosal 
tags, deep linear ulcers between the cheek and 
gums, lip swelling and (rarely) granulomatous 
cheilitis [20]. 
Reactive arthritis presents the symptom-
atic triad of arthritis, urethritis and conjunc-
tivitis. This pathology was previously known 
as Reiter syndrome and is one manifestation 
of reactive arthritis. Sometimes, this disease 
involves dermatological manifestations such 
as keratoderma, circinate balanitis and/or 
psoriasiform dermatitis (Figure 4). The disease 
is frequently triggered by infections that are 
sexually transmitted or can be postenteric; the 
primary trigger occurs 2–4 weeks before the 
appearance of the symptomatic triad. The geni-
tourinary syndrome is frequently associated 
with urethral infection transmitted by sexual 
intercourse, and the microorganism most com-
monly involved is Chlamydia. The postenteric 
syndrome that develops after acute diarrheic 
syndrome is caused by Salmonella, Shigella or 
Campylobacter. A few weeks after infection, 
some patients develop keratoderma blenorrhag-
icum on the soles and/or palms. Additionally, 
some patients may develop psoriasi form lesions, 
recurrent oral ulcers or a rash on the penile 
head referred to as circinate balanitis, which 
is frequently recurrent and can sometimes 
become difficult to manage [21]. 
Conclusion
Dermatological manifestations may be an ini-
tial clue or accompanying feature of spondylo-
arthritis. Therefore, the skin offers a way to 
detect associated comorbidities. Because of its 
accessibility, the skin represents an important 
source of information about the molecular 
mechanisms underlying the pathophysiology of 
spondyloarthritis and can be used as a reliable 




Figure 4. reactive arthritis. (A) Circinate balanitis and (B) keratoderma in 
reactive arthritis.
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0 weeks 12 weeks
Figure 5. A patient with psoriasis before and after treatment with anti-TNF-a. (A) Before 
treatment and (B) after treatment with anti-TNF-a. Immunohistochemistry of skin biopsies shows 
(C) TNF deposition and (d) decreased TNF deposition after treatment.
Future perspective
With the notion that spondyloarthritis is an 
inf lammatory disease, current therapeutic 
approaches are focused on biological agents to 
ameliorate inflammation, the use of chimeric or 
human anti-TNF monoclonal anti bodies and 
recombinant anticytokine receptors (Figure 5). 
Recently, IL-12 and IL-23 blockage has been 
proposed as a new strategy to prevent the pro-
duction of TNF, IFN-g and IL-2 cytokines, and 
represents an effective way to arrest the polar-
ization of the Th17 phenotype, which drives 
inflammation in psoriasis and probably in other 
types of spondyloarthritis. This strategy is cur-
rently in use, and new biological agents with this 
effect are under evaluation. Another promising 
area for spondyloarthritis therapy is the manip-
ulation of the Toll-like receptors to ameliorate 
inflammation [22,23]. 
Future efforts may strive to manipulate 
gene expression because cytokines are largely 
regulated at the transcriptional level. It there-
fore seems reasonable to believe that emergent 
therapies based on the use of miRNAs will help 
in spondyloarthritis treatment. Such therapy is 
based on mRNA decay induced by AU-rich ele-
ments in miRNA. This approach may be able 
to regulate the expression of cytokines involved 
in inflammation. The principal candidate cyto-
kines are TNF, IL-23 and IL-20. Notably, the 
applicability of cytokine-encoding mRNA has 
been successfully used in experimental mod-
els and may be applicable for use in human 
beings. These novel treatments may open a 
new avenue to control disease at the transcrip-
tional level in the context of psoriasis and other 
s pondyloarthritic conditions [11]. 
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Executive summary
Background
  Spondyloarthritis is a group of inflammatory rheumatic diseases that share a common genetic predisposition.
  The spondyloarthritis family include ankylosing spondylitis, psoriatic arthritis, arthritis/spondylitis associated with inflammatory bowel 
disease, reactive arthritis, undifferentiated spondyloarthritis, uveitis associated with the B-27 antigen, atrio-ventricular block, aortic 
insufficiency and juvenile chronic arthritis.
  Spondyloarthritis mainly affects the spine, sacroiliac joints and ligaments.
  Extra-articular manifestations in organs such as the intestines, urinary tract, heart, eyes and skin are frequently observed.
  The onset of the disease occurs between the third and fourth decades of life, and also in a form called juvenile spondyloarthritis.
Etiology
  The etiology of spondyloarthritis is unknown; however, the interaction of multiple genes, environmental factors and immunological 
abnormalities are implicated in the pathogenesis of these diseases. 
  The spondyloarthritis has a history of preceding infection 1 month before the onset of arthritis/enthesitis/dactylitis.
  Over 90% of patients with ankylosing spondylitis carry the HLA-B27 allele. 
  Psoriasis is associated with a group of susceptibility genes called PSOR 1–7.
Psoriasis is the gold standard of skin involvement
  Psoriasis is a T-cell mediated inflammatory disease, which occurs mainly in the skin, ligaments and joints.
  An initial trigger such as an infection (Streptococcus, Klebsiella, virus), trauma (Koebner phenomenon), stress or drugs could set off the 
psoriasis.
  Psoriasis is a papulo-squamous and desquamative disorder related to epidermal proliferation, hyperkeratosis, skin regeneration, skin 
metabolism and inflammation.
  The fingernails are frequently involved, showing nail matrix psoriasis with pitting, leukonychia and nail-bed psoriasis with 
hyperkeratosis, onycholysis, erythorniquia, oil spots and splinter hemorrhages.
Other dermatologic manifestations of spondyloarthritis disease
  Crohn’s disease and reactive arthritis are probably the spondyloarthritic diseases with different cutaneous manifestations, as oral 
ulceration, erythema nodosum, pyoderma gangrenosum and thrombophlebitis.
  Reactive arthritis presents the symptomatic triad of arthritis, urethritis and conjunctivitis, and also involves dermatological 
manifestations such as keratoderma, circinate balanitis and/or psoriasiform dermatitis.
Conclusion
  Dermatological manifestations may be an initial clue or accompanying feature of spondyloarthritis. 
  The skin offers a way to detect associated comorbidities.
Future perspective
  With the notion that spondyloarthritis is an inflammatory disease, current therapeutic approaches are focused on biological agents as 
anti-TNF monoclonal antibodies and recombinant anticytokine receptors, to ameliorate inflammation.
  Future efforts may strive to manipulate gene expression because cytokines are largely regulated at the transcriptional level.
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